Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Medical Writing Market

ID: MRFR/MED/6898-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

์œ ํ˜•๋ณ„(์ž„์ƒ ๋ฌธ์„œ ์ž‘์„ฑ, ๊ทœ์ œ ๋ฌธ์„œ ์ž‘์„ฑ, ๊ณผํ•™ ๋ฌธ์„œ ์ž‘์„ฑ, ์งˆ๋ณ‘ ๋ฐ ์•ฝ๋ฌผ ๊ด€๋ จ ๋ฌธ์„œ ์ž‘์„ฑ), ์‘์šฉ ๋ถ„์•ผ๋ณ„(์˜ํ•™ ์ €๋„๋ฆฌ์ฆ˜, ์˜ํ•™ ๊ต์œก, ์˜๋ฃŒ ๋งˆ์ผ€ํŒ…) ๋ฐ ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„(์ œ์•ฝ ๋ฐ ์ƒ๋ช… ๊ณตํ•™ ํšŒ์‚ฌ, ๊ณ„์•ฝ ์—ฐ๊ตฌ ๊ธฐ๊ด€) ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์กฐ์‚ฌ ๋ณด๊ณ ์„œ ์ •๋ณด - 2032๋…„๊นŒ์ง€ ์˜ˆ์ธก

๊ณต์œ 
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Medical Writing Market Infographic
Purchase Options
  1. 1 ๋ณด๊ณ ์„œ ์„œ๋ฌธ
  2. 2 ์‹œ์žฅ ์†Œ๊ฐœ
    1. 2.1 ์ •์˜
    2. 2.2 ์—ฐ๊ตฌ ๋ฒ”์œ„
      1. 2.2.1 ์—ฐ๊ตฌ ๋ชฉํ‘œ
      2. 2.2.2 ๊ฐ€์ •
      3. 2.2.3 ํ•œ๊ณ„
  3. 3 ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก 
    1. 3.1 ๊ฐœ์š”
    2. 3.2 1์ฐจ ์—ฐ๊ตฌ
    3. 3.3 2์ฐจ ์—ฐ๊ตฌ
    4. 3.4 ์‹œ์žฅ ๊ทœ๋ชจ ์ถ”์ •
  4. 4 ์‹œ์žฅ ์—ญํ•™
    1. 4.1 ๊ฐœ์š”
    2. 4.2 ๋™์ธ
    3. 4.3 ์ œ์•ฝ
    4. 4.4 ๊ธฐํšŒ
  5. 5 ์‹œ์žฅ ์š”์ธ ๋ถ„์„
    1. 5.1 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ถ„์„
      1. 5.1.1 ๊ณต๊ธ‰์—…์ฒด์˜ ํ˜‘์ƒ๋ ฅ
      2. 5.1.2 ๊ตฌ๋งค์ž์˜ ํ˜‘์ƒ๋ ฅ
      3. 5.1.3 ์‹ ๊ทœ ์ง„์ž…์ž์˜ ์œ„ํ˜‘
      4. 5.1.4 ๋Œ€์ฒด์žฌ์˜ ์œ„ํ˜‘
      5. 5.1.5 ๊ฒฝ์Ÿ์˜ ๊ฐ•๋„
    2. 5.2 ๊ฐ€์น˜ ์‚ฌ์Šฌ ๋ถ„์„
  6. 6 ์œ ํ˜•๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜ํ•™ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ
    1. 6.1 ๊ฐœ์š”
    2. 6.2 ์ž„์ƒ ๋ฌธ์„œ ์ž‘์„ฑ
    3. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ์ง€์—ญ๋ณ„, 2020-2027
    4. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ๊ตญ๊ฐ€๋ณ„, 2020-2027
    5. 6.3 ๊ทœ์ œ ๋ฌธ์„œ ์ž‘์„ฑ
    6. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ์ง€์—ญ๋ณ„, 2020-2027
    7. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก ๊ตญ๊ฐ€๋ณ„ ์˜ˆ์ธก, 2020-2027
    8. 6.4 ๊ณผํ•™์  ๊ธ€์“ฐ๊ธฐ
    9. ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2020-2027
    10. ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2020-2027
    11. 6.5 ์งˆ๋ณ‘ ๋ฐ ์•ฝ๋ฌผ ๊ด€๋ จ ๊ธ€์“ฐ๊ธฐ
    12. ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2020-2027
    13. ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2020-2027
    14. 6.6 ๊ธฐํƒ€
    15. ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2020-2027
    16. ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2020-2027
  7. 7 ์‘์šฉ ๋ถ„์•ผ๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜ํ•™ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ
    1. 7.1 ๊ฐœ์š”
    2. 7.2 ์˜ํ•™ ์ €๋„๋ฆฌ์ฆ˜
    3. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ์ง€์—ญ๋ณ„, 2020-2027
    4. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ๊ตญ๊ฐ€๋ณ„, 2020-2027
    5. 7.3 ์˜ํ•™ ๊ต์œก
    6. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ์ง€์—ญ๋ณ„, 2020-2027
    7. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ๊ตญ๊ฐ€๋ณ„, 2020-2027
    8. 7.4 ์˜๋ฃŒ ๋งˆ์ผ€ํŒ…
    9. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ์ง€์—ญ๋ณ„, 2020-2027
    10. ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, ๊ตญ๊ฐ€๋ณ„, 2020-2027
  8. 8 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ
    1. 8.1 ๊ฐœ์š”
    2. 8.2 ์ œ์•ฝ ๋ฐ ์ƒ๋ช…๊ณตํ•™ ๊ธฐ์—…
    3. 8.3 ์ž„์ƒ์‹œํ—˜์ˆ˜ํƒ๊ธฐ๊ด€(CROS)
  9. 9 ์ง€์—ญ๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ
    1. 9.1 ๊ฐœ์š”
    2. 9.2 ์•„๋ฉ”๋ฆฌ์นด
      1. 9.2.1 ๋ถ๋ฏธ
        1. 9.2.1.1 ๋ฏธ๊ตญ
        2. 9.2.1.2 ์บ๋‚˜๋‹ค
      2. 9.2.2 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด
    3. 9.3 ์œ ๋Ÿฝ
      1. 9.3.1 ์„œ์œ ๋Ÿฝ
        1. 9.3.1.1 ๋…์ผ
        2. 9.3.1.2 ํ”„๋ž‘์Šค
        3. 9.3.1.3 ์ดํƒˆ๋ฆฌ์•„
        4. 9.3.1.4 ์ŠคํŽ˜์ธ
        5. 9.3.1.5 ์˜๊ตญ
        6. 9.3.1.6 ๊ธฐํƒ€ ์„œ์œ ๋Ÿฝ
      2. 9.3.2 ๋™์œ ๋Ÿฝ
    4. 9.4 ์•„์‹œ์•„ ํƒœํ‰์–‘
      1. 9.4.1 ์ผ๋ณธ
      2. 9.4.2 ์ค‘๊ตญ
      3. 9.4.3 ์ธ๋„
      4. 9.4.4 ํ˜ธ์ฃผ
      5. 9.4.5 ํ•œ๊ตญ
      6. 9.4.6 ๊ธฐํƒ€ ์•„์‹œ์•„ ํƒœํ‰์–‘
    5. 9.5 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด
      1. 9.5.1 ์ค‘๋™
      2. 9.5.2 ์•„ํ”„๋ฆฌ์นด
  10. 10 ํšŒ์‚ฌ ํ˜„ํ™ฉ
    1. 10.1 ๊ฐœ์š”
    2. 10.2 ๊ฒฝ์Ÿ ๋ถ„์„
    3. 10.3 ์‹œ์žฅ ์ ์œ ์œจ ๋ถ„์„
    4. 10.4 ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ์˜ ์ฃผ์š” ์„ฑ์žฅ ์ „๋žต
    5. 10.5 ๊ฒฝ์Ÿ ๋ฒค์น˜๋งˆํ‚น
    6. 10.6 ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ์˜ ๊ฐœ๋ฐœ ๊ฑด์ˆ˜ ๊ธฐ์ค€ ์„ ๋„ ๊ธฐ์—…
    7. 10.7 ์ฃผ์š” ๊ฐœ๋ฐœ ๋ฐ ์„ฑ์žฅ ์ „๋žต
      1. 10.7.1 ์‹ ์ œํ’ˆ ์ถœ์‹œ/์„œ๋น„์Šค ๋ฐฐํฌ
      2. 10.7.2 ์ธ์ˆ˜ ํ•ฉ๋ณ‘
      3. 10.7.3 ํ•ฉ์ž‘ ํˆฌ์ž
    8. 10.8 ์ฃผ์š” ๊ธฐ์—… ์žฌ๋ฌด ๋งคํŠธ๋ฆญ์Šค ๋ฐ ์‹œ์žฅ ๋น„์œจ
      1. 10.8.1 ๋งค์ถœ ๋ฐ ์˜์—… ์ด์ต 2020
      2. 10.8.2 ์ฃผ์š” ๊ธฐ์—… R&D ์ง€์ถœ 2020
      3. 10.8.3 ์ฃผ์š” ๊ธฐ์—… ์ž๋ณธ ์‹œ์žฅ ๋น„์œจ
  11. 11 ํšŒ์‚ฌ ํ”„๋กœํ•„
    1. 11.1 Parexel International Corporation
      1. 11.1.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.1.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.1.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.1.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.1.5 SWOT ๋ถ„์„
      6. 11.1.6 ์ฃผ์š” ์ „๋žต
    2. 11.2 Freyr Solutions
      1. 11.2.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.2.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.2.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.2.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.2.5 SWOT ๋ถ„์„
      6. 11.2.6 ์ฃผ์š” ์ „๋žต
    3. 11.3 Cactus Communications
      1. 11.3.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.3.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.3.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.3.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.3.5 SWOT ๋ถ„์„
      6. 11.3.6 ์ฃผ์š” ์ „๋žต
    4. 11.4 Covance
      1. 11.4.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.4.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.4.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.4.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.4.5 SWOT ๋ถ„์„
      6. 11.4.6 ์ฃผ์š” ์ „๋žต
    5. 11.5 IQVIA
      1. 11.5.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.5.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.5.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.5.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.5.5 SWOT ๋ถ„์„
      6. 11.5.6 ์ฃผ์š” ์ „๋žต
    6. 11.6 Omics International
      1. 11.6.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.6.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.6.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.6.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.6.5 SWOT ๋ถ„์„
      6. 11.6.6 ์ฃผ์š” ์ „๋žต
    7. 11.7 SYNCHROGENIX
      1. 11.7.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.7.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.7.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.7.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.7.5 SWOT ๋ถ„์„
      6. 11.7.6 ์ฃผ์š” ์ „๋žต
    8. 11.8 SIRO CLINPHARM
      1. 11.8.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.8.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.8.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.8.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.8.5 SWOT ๋ถ„์„
      6. 11.8.6 ์ฃผ์š” ์ „๋žต
    9. 11.9 INCLIN, INC.
      1. 11.9.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.9.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.9.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.9.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.9.5 SWOT ๋ถ„์„
      6. 11.9.6 ์ฃผ์š” ์ „๋žต
    10. 11.10 Clinexa Life Sciences Pvt.
      1. 11.10.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 11.10.2 ์œ ํ˜• ๊ฐœ์š”
      3. 11.10.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 11.10.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 11.10.5 SWOT ๋ถ„์„
      6. 11.10.6 ์ฃผ์š” ์ „๋žต
    11. 11.11 ๊ธฐํƒ€
  12. 12 ๋ถ€๋ก
    1. 12.1 ์ฐธ๊ณ ๋ฌธํ—Œ
    2. 12.2 ๊ด€๋ จ ๋ณด๊ณ ์„œ
    3. ?
    4. ํ‘œ ๋ชฉ๋ก
    5. ํ‘œ 1 ๊ธ€๋กœ๋ฒŒ ์˜ํ•™ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ ๊ฐœ์š”, 2020-2027
    6. ํ‘œ 2 ๊ธ€๋กœ๋ฒŒ ์˜ํ•™ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    7. ํ‘œ 3 ์œ ํ˜•๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    8. ํ‘œ 4 ์‘์šฉ ํ”„๋กœ๊ทธ๋žจ๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    9. ํ‘œ 5 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    10. ํ‘œ 6 ์ง€์—ญ๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    11. ํ‘œ 7 ๋ถ๋ฏธ: ์œ ํ˜•๋ณ„ ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    12. ํ‘œ 8 ๋ถ๋ฏธ ๋ฏธ๊ตญ: ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    13. ํ‘œ 9 ๋ถ๋ฏธ: ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    14. ํ‘œ 10 ๋ฏธ๊ตญ: ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    15. ํ‘œ 11 ๋ฏธ๊ตญ: ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    16. ํ‘œ 12 ๋ฏธ๊ตญ: ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    17. ํ‘œ 13 ์บ๋‚˜๋‹ค: ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) ๋ฐฑ๋งŒ)
    18. ํ‘œ 14 ์บ๋‚˜๋‹ค: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    19. ํ‘œ 15 ์บ๋‚˜๋‹ค: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    20. ํ‘œ 16 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    21. ํ‘œ 17 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    22. ํ‘œ 18 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    23. ํ‘œ 19 ์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    24. ํ‘œ 20 ์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์‘์šฉ ํ”„๋กœ๊ทธ๋žจ๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    25. ํ‘œ 21 ์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    26. ํ‘œ 22 ์„œ์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    27. ํ‘œ 23 ์„œ์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์‘์šฉ ํ”„๋กœ๊ทธ๋žจ๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    28. ํ‘œ 24 ์„œ์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    29. ํ‘œ 25 ๋™์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    30. ํ‘œ 26 ๋™์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    31. ํ‘œ 27 ๋™์œ ๋Ÿฝ: ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    32. ํ‘œ 28 ์•„์‹œ์•„ ํƒœํ‰์–‘: ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    33. ํ‘œ 29 ์•„์‹œ์•„ ํƒœํ‰์–‘: ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) ์˜์–ด:
    34. ํ‘œ 30 ์•„์‹œ์•„ ํƒœํ‰์–‘: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    35. ํ‘œ 31 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    36. ํ‘œ 32 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์‘์šฉ ํ”„๋กœ๊ทธ๋žจ๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    37. ํ‘œ 33 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด: ์˜๋ฃŒ ๊ธ€์“ฐ๊ธฐ ์‹œ์žฅ, ์‘์šฉ ํ”„๋กœ๊ทธ๋žจ๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    38. ํ‘œ 33 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด: ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2020-2027(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ)
    39. ?
    40. ๊ทธ๋ฆผ ๋ชฉ๋ก
    41. ๊ทธ๋ฆผ 1 ์—ฐ๊ตฌ ํ”„๋กœ์„ธ์Šค
    42. ๊ทธ๋ฆผ 2 ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ์˜ ์‹œ์žฅ ๊ตฌ์กฐ
    43. ๊ทธ๋ฆผ 3 ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ์˜ ์‹œ์žฅ ์—ญํ•™
    44. ๊ทธ๋ฆผ 4 ์œ ํ˜•๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020(%)
    45. ๊ทธ๋ฆผ 5 ์‘์šฉ ํ”„๋กœ๊ทธ๋žจ๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020(%)
    46. ๊ทธ๋ฆผ 6 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020(%)
    47. ๊ทธ๋ฆผ 7 ์ง€์—ญ๋ณ„ ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020๋…„(%)
    48. ๊ทธ๋ฆผ 8 ์•„๋ฉ”๋ฆฌ์นด: ์ง€์—ญ๋ณ„ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020๋…„(%)
    49. ๊ทธ๋ฆผ 9 ๋ถ๋ฏธ: ๊ตญ๊ฐ€๋ณ„ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020๋…„(%)
    50. ๊ทธ๋ฆผ 10 ์œ ๋Ÿฝ: ์ง€์—ญ๋ณ„ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020๋…„(%)
    51. ๊ทธ๋ฆผ 11 ์„œ์œ ๋Ÿฝ: ๊ตญ๊ฐ€๋ณ„ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020๋…„(%)
    52. ๊ทธ๋ฆผ 12 ์•„์‹œ์•„ ํƒœํ‰์–‘: ๊ตญ๊ฐ€๋ณ„ ์˜๋ฃŒ ๋ฌธ์„œ ์ž‘์„ฑ ์‹œ์žฅ ์ ์œ ์œจ, 2020๋…„(%)
    53. ๊ทธ๋ฆผ 13 ์ค‘๋™ & ์•„ํ”„๋ฆฌ์นด: ๊ตญ๊ฐ€๋ณ„ ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ ์ ์œ ์œจ, 2020๋…„(%)
    54. ๊ทธ๋ฆผ 14 ๊ธ€๋กœ๋ฒŒ ์˜๋ฃŒ ๊ธฐ๋ก ์‹œ์žฅ: ํšŒ์‚ฌ ์ ์œ ์œจ ๋ถ„์„, 2020๋…„(%)
    55. ๊ทธ๋ฆผ 15 PAREXEL INTERNATIONAL CORPORATION.: ์ฃผ์š” ์žฌ๋ฌด ์ •๋ณด
    56. ๊ทธ๋ฆผ 16 PAREXEL INTERNATIONAL CORPORATION: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    57. ๊ทธ๋ฆผ 17 PAREXEL INTERNATIONAL CORPORATION: ์ง€์—ญ๋ณ„ ์ˆ˜์ต
    58. ๊ทธ๋ฆผ 18 FREYR SOLUTIONS: ์ฃผ์š” ์žฌ๋ฌด ์ •๋ณด
    59. ๊ทธ๋ฆผ 19 FREYR SOLUTIONS: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    60. ๊ทธ๋ฆผ 20 FREYR SOLUTIONS: ์ง€์—ญ๋ณ„ ์ˆ˜์ต
    61. ๊ทธ๋ฆผ 21 CACTUS COMMUNICATIONS: ์ฃผ์š” ์žฌ๋ฌด
    62. ๊ทธ๋ฆผ 22 CACTUS COMMUNICATIONS: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    63. ๊ทธ๋ฆผ 23 CACTUS COMMUNICATIONS: ์ง€์—ญ๋ณ„ ์ˆ˜์ต
    64. ๊ทธ๋ฆผ 24 COVANCE: ์ฃผ์š” ์žฌ๋ฌด
    65. ๊ทธ๋ฆผ 25 COVANCE: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    66. ๊ทธ๋ฆผ 26 COVANCE: ์ง€์—ญ๋ณ„ ์ˆ˜์ต
    67. ๊ทธ๋ฆผ 27 IQVIA: ์ฃผ์š” ์žฌ๋ฌด
    68. ๊ทธ๋ฆผ 28 IQVIA: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    69. ๊ทธ๋ฆผ 29 IQVIA: ์ง€์—ญ๋ณ„ ์ˆ˜์ต
    70. ๊ทธ๋ฆผ 30 OMICS INTERNATIONAL: ์ฃผ์š” ์žฌ๋ฌด
    71. ๊ทธ๋ฆผ 31 OMICS ๊ตญ์ œ: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    72. ๊ทธ๋ฆผ 32 OMICS ๊ตญ์ œ: ์ง€์—ญ๋ณ„ ์ˆ˜์ต
    73. ๊ทธ๋ฆผ 33 SYNCHROGENIX: ์ฃผ์š” ์žฌ๋ฌด ์ •๋ณด
    74. ๊ทธ๋ฆผ 34 SYNCHROGENIX: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    75. ๊ทธ๋ฆผ 35 SYNCHROGENIX: ์ง€์—ญ๋ณ„ ์ˆ˜์ต
    76. ๊ทธ๋ฆผ 36 SIRO CLINPHARM: ์ฃผ์š” ์žฌ๋ฌด ์ •๋ณด
    77. ๊ทธ๋ฆผ 37 SIRO CLINPHARM: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    78. ๊ทธ๋ฆผ 38 SIRO CLINPHARM: ์ง€์—ญ๋ณ„ ์ˆ˜์ต
    79. ๊ทธ๋ฆผ 39 INCLIN, INC: ์ฃผ์š” ์žฌ๋ฌด ์ •๋ณด
    80. ๊ทธ๋ฆผ 40 INCLIN, INC: ๋ถ€๋ฌธ๋ณ„ ์ˆ˜์ต
    81. ๊ทธ๋ฆผ 41 INCLIN, INC: ์ง€์—ญ ๋งค์ถœ
    82. ๊ทธ๋ฆผ 42 CLINEXA LIFE SCIENCES PVT: ์ฃผ์š” ์žฌ๋ฌด ์ •๋ณด
    83. ๊ทธ๋ฆผ 43 CLINEXA LIFE SCIENCES PVT: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ
    84. ๊ทธ๋ฆผ 44 CLINEXA LIFE SCIENCES PVT: ์ง€์—ญ ๋งค์ถœ
Case Study Cover Image
์‚ฌ๋ก€ ์—ฐ๊ตฌ

Aerospace & Defense

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization โœ“ โœ“ โœ“
Direct Access to Analyst โœ“ โœ“ โœ“
Deliverable Format โœ“ โœ“ โœ“
Platform Access โœ— โœ— โœ“
Discount on Next Purchase 10% 15% 15%
Printable Versions โœ— โœ— โœ“